companydata.dkcompanydata.dk

Hemab ApS: Financial statements 2023

CVR: 40837590

Source: annual report 2023, Danish Business Authority

01/01/202331/12/2023

Hemab ApS (CVR 40837590) has filed annual accounts for 2023. In 2023, the company reported a net result of USD -22,783,000 compared with DKK -156,407,000 the year before. Equity in the 2023 report amounted to USD 136,196,000. The solvency ratio was 97.6%. The company had 21 employees in the financial year.

Profit/Loss
USD -22,783,000
Equity
USD 136,196,000
Total Assets
USD 139,476,000
Employees
21

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2023---22.8 mio. USD136.2 mio. USD21
2022---156.4 mio.6.1 mio.10
2021---35.2 mio.68 mio.3

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2023

Hemab ApS: The 2022 annual report is outJul 3, 2023

Hemab ApS has published its annual report for 2022. The net result was DKK -156,407,000.

Johan Henrik Faber steps down as director of Hemab ApSMar 1, 2023

As of March 1, 2023, Johan Henrik Faber has stepped down as director of Hemab ApS.

Benny Sørensen joins the board of Hemab ApSFeb 15, 2023

As of February 15, 2023, Benny Sørensen has joined the board of directors of Hemab ApS.

Daniel Becker joins the board of Hemab ApSFeb 15, 2023

As of February 15, 2023, Daniel Becker has joined the board of directors of Hemab ApS.

Uya Chuluunbaatar joins the board of Hemab ApSFeb 15, 2023

As of February 15, 2023, Uya Chuluunbaatar has joined the board of directors of Hemab ApS.

Thomas Dal Stenfeldt Batchelor leaves the board of Hemab ApSFeb 15, 2023

As of February 15, 2023, Thomas Dal Stenfeldt Batchelor has left the board of directors of Hemab ApS.

About Hemab ApS

Hemab ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ebumab Hemophilia ApS. The management consists of Benny Sørensen and Mads Nikolaj Behrndt-Eriksen. The board consists of John Michael Maraganore (chair), Akshay Krishnadas Vaishnaw, Benny Sørensen and Linda Catharina Bain. The company is owned by Hemab Therapeutics Holdings, Inc.. According to the 2025 annual report, the company had an average of 54 employees. Equity in the 2025 report amounted to USD 196,000.

Source: annual report 2025, Danish Business Authority

Other financial years